Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
- 18 July 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (4), 318-325
- https://doi.org/10.1016/j.clcc.2021.07.003
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 studyAnnals of Oncology, 2017
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trialsAnnals of Oncology, 2017
- The Value of Multidisciplinary Team Meetings for Patients with Gastrointestinal Malignancies: A Systematic ReviewAnnals of Surgical Oncology, 2017
- CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209).Journal of Clinical Oncology, 2017
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyThe Lancet Oncology, 2015
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targetsNature Communications, 2015
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009